Skip to main content

Research Repository

Advanced Search

Outputs (794)

Ethnicity and socio-economic status affects the incidence and survival of hepatosplenic T-cell lymphoma (2024)
Journal Article
Bishton, M. J., Crooks, C. J., Card, T. R., & West, J. (2024). Ethnicity and socio-economic status affects the incidence and survival of hepatosplenic T-cell lymphoma. British Journal of Haematology, 204(6), 2222-2226. https://doi.org/10.1111/bjh.19371

To address the lack of contemporary population-based epidemiological studies of hepatosplenic T-cell lymphoma (HSTCL), we undertook a population-based study of ICD-O-3-coded HSTCL in England. We used the National Cancer Registration Dataset and linke... Read More about Ethnicity and socio-economic status affects the incidence and survival of hepatosplenic T-cell lymphoma.

Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline (2023)
Journal Article
Cox, M. F., Mackenzie, S., Low, R., Brown, M., Sanchez, E., Carr, A., Carpenter, B., Bishton, M., Duncombe, A., Akpabio, A., Kulasekararaj, A., Sin, F. E., Jones, A., Kavirayani, A., Sen, E. S., Quick, V., Dulay, G. S., Clark, S., Bauchmuller, K., Tattersall, R. S., & Manson, J. J. (2024). Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline. The Lancet Rheumatology, 6(1), e51-e62. https://doi.org/10.1016/s2665-9913%2823%2900273-4

Haemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome characterised by persistently activated cytotoxic lymphocytes and macrophages, which, if untreated, leads to multiorgan dysfunction and death. HLH should be considered in any a... Read More about Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline.

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience (2023)
Journal Article
Shotton, R., Broadbent, R., Alchawaf, A., Mohamed, M. B., Gibb, A., Martinez-Calle, N., Fox, C. P., Bishton, M., Pender, A., Gleeson, M., Cunningham, D., Davies, A. J., Yadollahi, S., Eyre, T. A., Collins, G. P., Djebbari, F., Kassam, S., Garland, P., Watts, E., Osborne, W., …Linton, K. M. (2024). Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience. Blood Advances, 8(4), 878-888. https://doi.org/10.1182/bloodadvances.2023011305

Bendamustine is among the most effective chemotherapeutics for indolent B-cell non- Hodgkin lymphomas (iNHL), but trial reports of significant toxicity, including opportunistic infections and excess deaths, led to prescriber warnings. We conducted a... Read More about Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.

Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom (2023)
Journal Article
Minson, A., Hamad, N., Di Ciaccio, P., Talaulikar, D., Ku, M., Ratnasingam, S., Cheah, C., Yannakou, C. K., Bishton, M., Ng, Z. Y., Agrawal, S., McQuillan, A., Johnston, A., Choong, E., Wong, K., McQuillan, J., Beekman, A., Hawkes, E., & Dickinson, M. (2024). Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom. British Journal of Haematology, 204(2), 548-554. https://doi.org/10.1111/bjh.19179

Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma characterised by a heterogeneous clinical course. Patients can often receive sequential treatments, yet these typically yield diminishing periods of disease control, raising questions about... Read More about Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom.

Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression (2023)
Journal Article
Atallah, N. M., Haque, M., Quinn, C., Toss, M. S., Makhlouf, S., Ibrahim, A., …Rakha, E. (2023). Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression. European Journal of Cancer, 195, Article 113371. https://doi.org/10.1016/j.ejca.2023.113371

Background: Breast cancer (BC) expressing low levels of human epidermal growth factor receptor 2 (HER2 Low) is an emerging category that needs further refining. This study aims to provide a comprehensive clinico-pathological and molecular profile of... Read More about Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression.

Diagnosis and Management of Mantle Cell Lymphoma: A British Society for Haematology Guideline (2023)
Journal Article
Eyre, T. A., Bishton, M. J., McCulloch, R., O'Reilly, M., Menon, G., Iyengar, S., Lewis, D., Lambert, J., Linton, K. M., McKay, P., & Haemato-Oncology Task Force of the British Society for Haematology, H.-O. T. F. O. T. B. S. F. H. (2024). Diagnosis and Management of Mantle Cell Lymphoma: A British Society for Haematology Guideline. British Journal of Haematology, 204(1), 108-126. https://doi.org/10.1111/bjh.19131

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma (2023)
Journal Article
Lewis, K. L., Jakobsen, L. H., Villa, D., Smedby, K. E., Savage, K. J., Eyre, T. A., …Pophali, P. A. (2023). High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma. Journal of Clinical Oncology, 41(35), 5376-5387. https://doi.org/10.1200/JCO.23.00365

PURPOSE
CNS progression or relapse is an uncommon but devastating complication of aggressive B-cell lymphoma. There is no consensus regarding the optimal approach to CNS prophylaxis. This study was designed to determine whether high-dose methotrexat... Read More about High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.

1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018 (2023)
Journal Article
West, J., Stilwell, P., Liu, H., Ban, L., Bythell, M., Card, T., …Crooks, C. (2023). 1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018. Journal of Hematology and Oncology, 16, Article 56. https://doi.org/10.1186/s13045-023-01434-4

Haemophagocytic lymphohistiocytosis (HLH) is a lethal syndrome of excessive immune activation. We undertook a nationwide study in England of all cases of HLH diagnosed between 2003 and 2018, using linked electronic health data from hospital admission... Read More about 1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018.

Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer (2023)
Journal Article
Lashen, A. G., Toss, M. S., Wootton, L., Green, A. R., Mongan, N. P., Madhusudan, S., & Rakha, E. (2023). Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer. Histopathology, 83(3), 414-425. https://doi.org/10.1111/his.14960

Background: Polo-like kinase-1 (PLK1) plays a crucial role in cell cycle progression,and it is considered a potential therapeutic target in many cancers. Although the role of PLK1 is well established in triple negative breast cancer (TNBC) as an onco... Read More about Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer.